Joinn Laboratories (China) Co (SHSE:603127) Marketable Securities: ¥1,558 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:603127 Joinn Laboratories (China) Co Ltd SHSE:603127
70 GF Score
Price ¥41.37
GF Value ¥16.94
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Joinn Laboratories (China) Co Marketable Securities?

Joinn Laboratories (China) Co SHSE:603127 -2.82% 70 Marketable Securities is ¥1,558 Mil as of Jun. 2026. GuruFocus rates SHSE:603127 with a GF Score™ of 70/100 and a GF Value™ of ¥16.94 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Joinn Laboratories (China) Co's Marketable Securities for the quarter that ended in Jun. 2026 was ¥1,558 Mil.

Joinn Laboratories (China) Co's annual Marketable Securities increased from Dec. 2023 (¥373 Mil) to Dec. 2024 (¥1,396 Mil) and increased from Dec. 2024 (¥1,396 Mil) to Dec. 2025 (¥1,718 Mil).

Joinn Laboratories (China) Co  (SHSE:603127) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Joinn Laboratories (China) Co Marketable Securities Related Terms

Joinn Laboratories (China) Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Joinn Laboratories (China) Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Joinn Laboratories (China) Co Marketable Securities Chart

Joinn Laboratories (China) Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 680.98 408.47 373.35 1,396.12 1,718.32

Joinn Laboratories (China) Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1,503.83 1,575.19 1,718.32 1,510.90 1,558.42
SHSE:603127
70GF Score
Joinn Laboratories (China) Co Ltd SHSE:603127
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Joinn Laboratories (China) Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ¥1,558 Mil mean?
Joinn Laboratories (China) Co (SHSE:603127) has a Marketable Securities of ¥1,558 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Joinn Laboratories (China) Co and its competitors.
Is Joinn Laboratories (China) Co's Marketable Securities too high?
Joinn Laboratories (China) Co's current Marketable Securities is ¥1,558 Mil. Overall, Joinn Laboratories (China) Co has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Joinn Laboratories (China) Co's Marketable Securities compare to TMO and DHR?
Joinn Laboratories (China) Co's Marketable Securities of ¥1,558 Mil can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Medical Diagnostics & Research company?
A good Marketable Securities depends on the Medical Diagnostics & Research industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Joinn Laboratories (China) Co and its competitors. Joinn Laboratories (China) Co's current Marketable Securities is ¥1,558 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Joinn Laboratories (China) Co stock overvalued right now?
Based on GuruFocus' analysis, Joinn Laboratories (China) Co (SHSE:603127) is currently considered Significantly Overvalued. The stock's GF Value™ is ¥16.94, compared to a current price of ¥41.37 — trading 144.2% above its estimated fair value. The current Marketable Securities is ¥1,558 Mil. Joinn Laboratories (China) Co's overall GF Score™ is 70/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Joinn Laboratories (China) Co (SHSE:603127), the current Marketable Securities is ¥1,558 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Joinn Laboratories (China) Co (SHSE:603127) Overvalued in 2026?

Based on GuruFocus' analysis, Joinn Laboratories (China) Co stock appears to be overvalued. The current stock price of ¥41.37 is trading 144.2% above its estimated GF Value™ of ¥16.94. GuruFocus considers Joinn Laboratories (China) Co to be Significantly Overvalued.

Key valuation signals for SHSE:603127:

  • Marketable Securities: ¥1,558 Mil
  • GF Value™: ¥16.94 vs. price of ¥41.37 (144.2% above fair value)
  • GF Score™: 70/100 with 6 warning signs

No single metric tells the full story. See the SHSE:603127 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Joinn Laboratories (China) Co Business Description

Other Exchanges 06127:Hong Kong
Address A5 Rongjing East Street, Beijing Economic-Technological Development Area, Beijing, CHN, 100176
Joinn Laboratories (China) Co Ltd is a PRC-based company, along with its subsidiary, it is engaged in contract research organisation (CRO) services. It operates in three segments: Non-clinical studies services offer drug safety assessment, drug metabolism and pharmacokinetics (DMPK) studies, and pharmacology and efficacy studies; Clinical trial & related services provide clinical CRO services, co-managed phase I clinical research units, and bioanalytical servicesl services; and Sales of research models engages in the design, production, breeding and sales of research models, non-human primates and rodents. The majority of revenue comes from the Non-Clinical studies services. Its geographical areas are China, the United States, and Other countries, of which the majority are from China.
70GF Score

Get the complete analysis for SHSE:603127

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥41.37
Price
¥16.94
GF Value